Nataliya Agafonova
Known title: Chief Medical OfficerCIK: 0001985443
Associated companies
Transaction History
| LGVN | ▼ Sell | Tax Withholding | 2,913 | $8K | 10/1/2026 | View on chart |
| LGVN | ▲ Buy | Grant | 286,000 | $0 | 8/19/2026 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 22,505 | $16K | 7/1/2026 | View on chart |
| LGVN | ▲ Buy | Grant | 250,000 | $0 | 5/1/2026 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 13,145 | $15K | 4/1/2026 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 10,250 | $6K | 1/2/2026 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 11,883 | $9K | 10/1/2025 | View on chart |
| LGVN | ▲ Buy | Grant | 102,000 | $0 | 7/15/2025 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 7,431 | $10K | 7/1/2025 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 7,566 | $11K | 4/1/2025 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 6,120 | $11K | 1/2/2025 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 5,316 | $10K | 10/1/2024 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 14,391 | $35K | 8/15/2024 | View on chart |
| LGVN | ▲ Buy | Grant | 175,750 | $0 | 8/15/2024 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 308 | $872 | 5/2/2024 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 3,074 | $4K | 1/2/2024 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 3,059 | $7K | 10/2/2023 | View on chart |
| LGVN | ▼ Sell | Tax Withholding | 3,081 | $10K | 8/18/2023 | View on chart |
| LGVN | ▲ Buy | Grant | 30,000 | $0 | 7/24/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Longeveron to speak at three longevity investment conferences
Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.
Longeveron to speak at three longevity investment conferences. Longeveron has announced it will participate in three upcoming conferences focused on longevity and aging research. These events provide a platform for the company to discuss its scientific progress with investors and industry professionals. The stock is currently trading well below its 52-week high, with an average analyst target of $61.25.